On October 7, 2020 Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, reported that abstracts submitted for two of its drug candidates have been selected for presentation at the Molecular Targets and Cancer Therapeutics virtual symposium hosted by the European Organisation for Research and Treatment of Cancer (EORTC), the National Cancer Institute (NCI) and the American Association for Cancer Research (AACR) (Free AACR Whitepaper) on Oct. 24-25 (Press release, Turning Point Therapeutics, OCT 7, 2020, View Source [SID1234568193]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The abstracts include a late-breaker submission selected for an oral presentation by David Hong, M.D., Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, of early clinical data for Turning Point’s novel MET/SRC/CSF1R inhibitor, TPX-0022; and two poster presentations of preclinical data for lead drug candidate repotrectinib demonstrating first, an increase in the effectiveness of a KRAS-G12C inhibitor via the simultaneous inhibition of SRC, FAK and JAK2 kinases; and second to be presented in a poster discussion session, potent anti-tumor activity as a monotherapy and in combination with chemotherapy in neuroblastoma cell lines and pediatric patient derived xenograft models.
Details for the presentations are as follows:
Title: First-in-human safety, pharmacokinetics, and preliminary efficacy of TPX-0022, a novel inhibitor of MET/SRC/CSF1R in patients with advanced solid tumors harboring genetic alterations in MET
Session: Plenary Session 1, Late Breaking and Best Proffered Papers
Date and Time: Saturday, 24 October 2020 – 15:05 CET (9:05 a.m. ET)
Title: Repotrectinib Increases KRASG12C Inhibitor Effectiveness Via Simultaneous Inhibition of SRC, FAK, and JAK2
Session: Drug Resistance and Modifiers
Date: Saturday, 24 October 2020, Session Code 310
Title: Repotrectinib, a next-generation ALK/ROS1/NTRK 1-3 inhibitor, has potent antiproliferative and anti-tumor activity as monotherapy and in combination with chemotherapy in neuroblastoma cell lines and pediatric patient derived xenograft models
Session: Next Generation Targeted Therapies A
Date and Time: Saturday, 24 October 2020 – 22:00 – 23:20 CET (4:00 p.m. – 5:30 p.m. ET)